Cardinal Health (CHN) Raises 2026 Profit Forecast Amid Specialty Drug and Biosimilar Demand Surge

Cardinal Health (CHN) raised its 2026 annual adjusted EPS guidance to $10.15-$10.35, up from $10, as Q4 revenue of $65.63B beat estimates of $64.14B and adjusted EPS of $2.63 surpassed $2.36. The revision reflects strong specialty drug and biosimilar demand, with the pharmaceutical and specialty solutions segment reaching $60.7B in the quarter ended December 31, up 19% YoY. The company projects specialty revenue of over $50B in 2026, driven by a 30%+ growth in its biopharma solutions unit, supported by acquisitions of cancer center operators to diversify beyond core distribution.